Document is current

Article History

Received: 16 November 2022

Accepted: 3 December 2022

First Online: 24 December 2022

Declarations

:

: The study protocol is compliant with ethical practices and will be conducted according to principles outlined in the Declaration of Helsinki. Informed written consent to participate in the study will be obtained from all participants. Where this is not possible due to quick discharge from hospital (i.e., before day 2 on the acute stroke unit when written consent is expected to be obtained), verbal consent will be obtained via phone call, as approved by the ethics committee. As the participants who discharge before day 2 are representative of a subgroup of patients (i.e., with no or resolved symptoms of stroke), it is important to include a secondary verbal consent process to ensure these participants could be included in the study so that results are not skewed or impacted. The study protocol has been submitted to the Mater Misericordiae Ltd. HREC, reference number: HREC/MML/66933, V9 Sep2022. Ethics approval obtained on 4 November 2020. Human research ratification/registration of external approval submitted to The University of Queensland and approved on 23 March 2021, identifier: 2021/HE000615. Site-Specific Assessment (SSA) submitted to the Mater Misericordiae Ltd. Research Governance Office (RGO), reference number: MSSA/MRGO/66933. Governance approval obtained on 14 February 2021. The study was prospectively submitted and retrospectively registered on 09 April 2021 with the Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12621000380897, . All protocol amendments will be approved by the HREC and reported to ANZCTR.

: Not applicable.

: The authors declare that they have no competing interests.